NCT05823779

Brief Summary

This study is an observational, cohort, prospective study looking at the frequency of Herpes Simplex Virus (HSV) 1 and or 2 outbreaks in HIV positive patients who's HIV virus is controlled on highly active anti-retroviral therapy. We will be enrolling fifty (50) patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Apr 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2022

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

April 9, 2023

Completed
12 days until next milestone

First Posted

Study publicly available on registry

April 21, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

April 21, 2023

Status Verified

April 1, 2023

Enrollment Period

2.8 years

First QC Date

April 9, 2023

Last Update Submit

April 9, 2023

Conditions

Keywords

HIV, Herpes Simplex 1, Herpes Simplex 2

Outcome Measures

Primary Outcomes (1)

  • Epidemiology

    The frequency of HSV outbreaks in HIV positive patients.

    48 weeks

Secondary Outcomes (1)

  • Co Morbidity

    48 weeks

Interventions

We will be drawing blood for verify HIV status, HSV 1 or 2 antibodies, CD4 and HIV-PCR

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are positive for HIV antibodies and IgG or IgM antibodies to Herpes Simplex Virus 1 or Herpes Simplex Virus 2

You may qualify if:

  • Subject must be 18 years or older at the time of screening
  • Males, Females, Transgender Male and Transgender Females
  • HIV positive
  • Positive antibody to HSV- 1/and or HSV-2
  • If Female of child baring potential, documented negative pregnancy test at the time of screening.

You may not qualify if:

  • Active opportunistic infection
  • Current chemotherapy
  • Unable to give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Global Research Institute

Los Angeles, California, 90036, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

We are retaining patient serum

MeSH Terms

Conditions

Acquired Immunodeficiency Syndrome

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

HIV InfectionsBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesSlow Virus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

Jorge E Rodriguez, M.D.

CONTACT

Michael S Gottlieb, M.D.

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 9, 2023

First Posted

April 21, 2023

Study Start

April 1, 2022

Primary Completion

December 31, 2024

Study Completion

April 1, 2025

Last Updated

April 21, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will share

Share with Rational Vaccine

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR
Time Frame
At conclusion of the study
Access Criteria
Total Access

Locations